YH32364

Yuhan Corporation · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	YH32364
Sponsor	Yuhan Corporation
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

YH32364 CI brief — competitive landscape report
YH32364 updates RSS · CI watch RSS
Yuhan Corporation portfolio CI